Loading profile
Loading sourced facts.
01 Finding sources
02 Reading evidence
03 Filing the card
Loading profile
01 Finding sources
02 Reading evidence
03 Filing the card
Recursion is a publicly traded TechBio company that uses large-scale automated cell imaging and AI to discover and develop drugs, running its own clinical pipeline in oncology, rare disease, and neuroscience.
No filing, no announced round, no reported figure.
No public funding found.
Chris Gibson, Co-Founder; Chairman (as of Jan 2026; previously CEO Nov 2013–Jan 2026)[4][5][13][23][24][25][26][27]
Blake Borgeson, Co-Founder; Board Member (previously CTO Nov 2013–Jul 2018)[4][5][13][23][24][25][26][27]
CHRISTOPHER CORY GIBSON, Co-Founder & Chair, Recursion (NASDAQ:RXRX) | Co-Founder & CEO, BOXBOX | Co-Founder, Project Gamma | Boards: Cellino, Salt Lake Tribune, BioHive | Advisor: A-Alpha Bio | Angel & friend to the best deep-tech companies[4][5][13][23][24][25][26][27]
Ben Taylor, Chief Financial Officer and President of Recursion UK[14][15][16][17][18][19][20][21][22]
Najat Khan, CEO and President[14][15][16][17][18][19][20][21][22]
May 2026 · recursion.com
company
May 2026 · linkedin.com
vendor
Recursion is a publicly traded TechBio company that uses large-scale automated cell imaging and AI to discover and develop drugs, running its own clinical pipeline in oncology, rare disease, and neuroscience.
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Exscientia · exscientia.ai · Direct merger target: Exscientia's chemistry and ClinTech capabilities were absorbed into Recursion OS 2.0; named explicitly in Recursion's own leadership LinkedIn as the 2024 combination deal, making it the closest structural comparable on the AI-native drug...[6]
Insilico Medicine · insilico.com · Same buyer and workflow: integrated TechBio model using AI for end-to-end drug discovery with an internal pipeline, listed as a direct competitor to Recursion Pharmaceuticals on CBInsights and StartupHub alternatives pages.[35][37]
Schrödinger · schrodinger.com · Overlapping pharma R&D buyer and computational drug discovery workflow; listed among Recursion's top alternatives on CBInsights and ZoomInfo competitor pages; competes for the same pharma partnership budget on the platform-licensing side of Recursion's...[35][36]
Relay Therapeutics · relaytx.com · Same integrated TechBio model—proprietary computational platform feeding an internal clinical pipeline in oncology—listed as a comparable on CBInsights and StartupHub alternatives pages for Recursion.[35][37]
The customer proof is company-sourced only. No independent source in this ledger confirms it.[1]
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Filled in the side panel for invited readers. This card carries sourced facts only.
May 2026 · cbinsights.com
verified
May 2026 · tracxn.com
verified
May 2026 · stableenrich.dev
vendor
May 2026 · biospace.com
reported